Prévisions

L'objectif de cours moyen des analystes est de 7,74 € (+50,00 %). La médiane est de 7,74 € (+50,00 %).

Acheter	1
Conserver	0
Vendre	0

Actualités Accéder au fil d'actualités

CapsoVision: Q2 loss widens, stock falls sharply in after-hours trading

CapsoVision reported Q2 revenue of $3.6 million (+10%) and an adjusted EPS of -$0.15, missing the consensus of -$0.11. Gross margin fell to 51% and operating expenses rose 46% to $9.5 million, pressured by development costs, tariffs and price competition. Management expects a stronger second half, plans a US launch of "AI Highlights" after expected FDA approval and has an ATM program of up to $100 million available; the stock dropped sharply after hours. » Plus sur de.investing.com
CapsoVision introduces AI feature AI Highlights for CapsoCam Plus internationally

CapsoVision has announced the international launch of AI Highlights for the CapsoCam Plus system. The AI analyzes capsule endoscopy recordings during video processing, flags images suspected of clinically relevant findings, and is integrated into the CapsoView software and the CapsoCloud platform. The feature is available in markets where CapsoView/CapsoCloud are regulatory approved, including the EU; in the US, AI Highlights is not FDA‑approved and is not commercially available. The application is intended for trained medical professionals and does not replace clinical judgment. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, CAPSOVISION INC a réalisé un chiffre d'affaires de 3,19 M € et un bénéfice net de -6,55 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	3,19 M	13,49 %
Bénéfice brut	1,64 M	6,70 %
Bénéfice net	-6,55 M	67,05 %
EBITDA	-6,55 M	71,31 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	257,5 M €
Nombre d'actions	49,96 M
Plus haut/bas sur 52 semaines	13,22 € - 2,95 €
Dividendes	Non
Bêta	-2,49
Ratio P/E	-9,51
Ratio PEG	0,33
Ratio P/B	22,72
Ratio P/S	21,55

Profil de l'entreprise

Medizintechnikunternehmen, das fortschrittliche Kapselendoskopiesysteme (CapsoCam Plus, CapsoCam Colon) und KI-gestützte Bildgebungsplattformen für die gastrointestinale Diagnostik entwickelt